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ABSTRACT 
 Apelin and its receptor APJ constitute a signaling pathway best recognized as an 
important regulator of cardiovascular homeostasis. This multifunctional peptidergic 
system is currently being described to be involved in embryonic events which extend 
into vascular, ocular and heart development. Additionally, it is highly expressed in 
pulmonary tissue. Therefore, the aim of this study was to investigate the role of 
apelinergic system during fetal lung development. Immunohistochemistry and Western 
blot analysis were used to characterize apelin and APJ expression levels and cellular 
localization in normal fetal rat lungs, at five different gestational ages as well as in the 
adult. Fetal rat lung explants were cultured in vitro with increasing doses of apelin. 
Treated lung explants were morphometrically analyzed and assessed for MAPK 
signaling modifications. Both components of the apelinergic system are constitutively 
expressed in the developing lung, with APJ exhibiting monomeric, dimeric and 
oligomeric forms in the pulmonary tissue. Pulmonary epithelium also displayed 
constitutive nuclear localization of the receptor. Fetal apelin expression is higher than 
adult expression. Apelin supplementation inhibitory effect on branching morphogenesis 
was associated with a dose dependent decrease in p38 and JNK phosphorylation.  The 
results presented provide the first evidence of the presence of an apelinergic system 
operating in the developing lung. Our findings also suggest that apelin inhibits fetal 
lung growth by suppressing p38 and JNK signaling pathways. 
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1. INTRODUCTION 
The existence of the apelinergic system began to unfold in 1998 when APJ 
(angiotensin II receptor-like 1), a formerly orphan G-protein coupled receptor (GPCR), 
and its ligand were finally paired by Tatemoto and coworkers [45]. Apelin was 
identified as an endogenous ligand for APJ receptor. This peptide is translated as a 77-
amino acid precursor, which undergoes proteolytic maturation generating shorter active 
apelin peptides. Apelin-36 was the first of these shorter C-terminal sequences being 
described to bind and activate APJ [45]. Also apelin-17, apelin-13 and its pyroglutamyl 
isoform which is resistant to degradation, (Pyr1)-Apelin-13, were proven to act as 
functional ligands of APJ and in some cases exhibited much higher biological activity 
than apelin-36 [45,17,18,25,46]. 
Apelin receptor was originally identified as a receptor related to angiotensin II 
receptor 1, due to high homology between the two receptor proteins [38]. This receptor 
is 380 amino acid long, consists of seven transmembrane domains and also includes a 
signal sequence that allows agonist-independent nuclear localization, a feature that may 
be cell-specific [27]. GPCRs are the estimated targets of nearly half of all currently 
available clinically used drugs [11] and are key components of the signal transduction 
machinery [35]. Binding of apelin to APJ activates second messenger signaling 
cascades after coupling to G proteins, which results in activation of central signaling 
molecules such as mitogen-activated protein kinases (MAPKs) and the PI3K/AKT 
pathway that are responsible to instigate multiple biological responses [30,31,1,28]. 
The apelinergic system has a widespread pattern of distribution in human and 
animal tissues and its established physiological actions are extensive. Overall, apelin 
and APJ mRNA transcripts and respective peptides, are abundantly present in central 
nervous system and also in peripheral tissues such as vascular endothelium, heart, lung, 
kidney and mammary gland [18,25,40,32,10,21], suggesting a functional role of 
apelin/APJ in these tissues. Remarkably the bulk of the studies report cardiovascular 
actions of apelin/APJ. Moreover, this peptidergic system has been proposed to have a 
role in body fluid homeostasis, immunologic modulation, diabetes and obesity. 
[39,12,26,22,4]. Recently the apelinergic system has been described to promote 
embryonic and tumor angiogenesis [19,9,43]. Growing evidences of apelin/APJ 
involvement in embryonic events currently extend beyond vascular development, into 
ocular [20] and heart development [42,49,14]. 
Interesting findings regarding the apelinergic system clearly reveal that the lung 
is one of the organs with strongest expression of both ligand and receptor. Furthermore, 
emerging evidences of this system’s implications in embryonic development prompt the 
speculation that there might be an underlying role in embryonic lung development. 
However, the expression profile of this pair of proteins and their functional role during 
normal lung development is hitherto unknown. So far, the effects of apelin on lung 
development have been described only in one study that reports attenuation of lung 
injury in neonatal rats exposed to prolonged hyperoxia [47]. Therefore we proposed to 
investigate the Apelin-APJ system during fetal lung development. In this report a 
thorough characterization of both components of the apelinergic system by 
immunohistochemistry and western blot in several stages of fetal lung development is 
provided. We further investigated the role of this system in branching morphogenesis of 
the lung and the intracellular effectors implicated. 
  
2. MATERIALS AND METHODS 
2.1 Animal model and experimental design 
Animal experiments were performed according to the Portuguese law for animal 
welfare. Animals were housed in an accredited mouse house and treated as specified in 
the ‘Guide for the Care and Use of Laboratory Animals published by the US National 
Institutes of Health’s (National Institutes of Health Publication No.85-23, revised 1996). 
Sprague–Dawley female rats (225 g, Charles-River, Spain) were maintained in 
appropriate cages under controlled conditions, fed with commercial solid food and after 
mating they were checked for vaginal plug. The average pregnancy length in normal 
adult rat is of 21.5 days and the day of plugging was defined as gestational day 0.5 for 
time dating purposes. Pregnancies were confirmed by regular weightings. At different 
time-points [13.5, 15.5, 17.5, 19.5, and 21.5 days postconception (dpc)], pregnant 
female rats were sacrificed by rapid decapitation and fetuses were harvested by 
caesarean section. Fetuses were also sacrificed by decapitation, fetal and adult lungs 
were excised, processed and collected for Immunohistochemistry (IHC) or Western blot 
analysis. Regarding lung explant cultures, fetuses were harvested at 13.5 dpc and their 
lungs were dissected, cultured in vitro for four days and then collected for Western blot 
analysis. 
2.2 Western Blot analysis 
Protein lysates of 13.5 and 15.5 dpc excised lungs and protein lysates of pooled 
lung explants were obtained by homogenization of the fetal tissue with a pellet pestle 
motor (Kontes, USA) on ice; as for lungs of later gestational ages and adult samples a 
mini bead beater (Biospek Products Inc., USA) was used for homogenization. Different 
pooled lung samples for each gestational age and also the adult were used and three 
independent experiments were performed. Proteins were obtained according to Kling et 
al. [24]. Whole protein concentration was quantified by the Bradford method [3]. Either 
twenty five or ten micrograms of protein were loaded onto 12.5% or 10% acrylamide 
minigels under denaturing and reducing conditions, electrophoresed for approximately 2 
hours at 100 V at room temperature and then transferred onto nitrocellulose membranes 
(Hybond
TM
-C Extra GE Healthcare Life Sciences, UK) in a wet transfer system for 1 
hour. Blots were probed with antibodies to apelin [1:500; Apelin (FL-77), Santa Cruz 
Biotechnology Inc., USA], apelin receptor [1:500; APLNR (H-300), Santa Cruz 
Biotechnology Inc.] and non-phosporylated and phosporylated forms of p38, p44/42 
(ERK1/2) and JNK (1:1 000; Cell Signaling Technology Inc., USA) according to the 
manufacturer’s instructions. For loading control, blots were reprobed with β-tubulin 
antibody (1:150 000 Abcam, UK), which were previously incubated with EzWay
TM
 
Antibody Erasing Buffer (Komabiotech Inc., Korea) for primary and secondary 
antibody removal. Afterwards blots were incubated with a secondary horseradish 
peroxidase conjugate and developed with Super Signal West Femto Substrate (Pierce 
Biotechnology Inc., USA). The chemiluminescent signal was captured using a 
Chemidoc XRS (BioRad, USA) apparatus and subsequent densitometric analysis of 
nonsaturating bands was performed using Quantity One software (BioRad). 
2.3 Immunohistochemistry 
Immunostaining was performed on paraformaldehyde-fixed and paraffin-
embedded excised lungs and embryos. Five μm sections were placed onto glass 
microscope slides. Primary antibodies for apelin [1:50; Apelin (M-77), Santa Cruz 
Biotechology Inc.], and apelin receptor (APJ, Abcam Inc.) were used. Tissue sections 
were deparaffinized in xylene and rehydrated in ethanol, boiled in 10 mM citrate buffer 
for antigen retrieval and cooled down at room temperature. Incubation with the primary 
antibody occurred at 4ºC overnight. Negative control reactions included omission of the 
primary antibody and immunoreactive apelin and APJ staining were not observed in 
these cases. Sections were incubated with a labeled streptavidin-biotin 
immunoenzimatic antigen detection system (UltraVision Large Volume Detection 
System Anti-Polyvalent, Horseradish Peroxidase, Lab Vision Corporation, USA) 
according to manufacturer’s instructions. For visualization of the immune reaction, a 
diaminobenzidine tetrahydrochloride solution (Dako, Denmark) was used. Sections 
were finally counterstained with hematoxylin. The slides were observed and 
photographed with Olympus BX61 microscope (Olympus, Japan). The pictures 
presented are representative of six animals (N=6), twelve samples were examined for 
each gestational age as well as the adult and three independent experiments were 
performed. 
2.4 Fetal lung explant cultures 
Lungs were removed from 13.5 dpc embryos, harvested and dissected under a 
stereomicroscope (SZX16, Olympus). These were transferred to porous membranes 
(Isopore
TM
 membrane filters, Millipore, USA) previously presoaked in DMEM 
(Invitrogen, UK) and incubated in twenty-four-well culture plates (Nunc, Denmark). 
Three explants per membrane were positioned in a well-separated arrangement and 
these floating cultures were incubated at an air-medium interface in a chemically 
defined medium containing 50% DMEM, 50% F-12 nutrient mixture (Invitrogen) and 
supplemented with 100 mg/mL penicillin, 100 units/mL streptomycin (Invitrogen), 0.25 
mg/mL ascorbic acid (Sigma-Aldrich, USA) and 10% FCS (Invitrogen). Fetal lung 
explants were incubated in a 5% CO2 incubator at 37°C for 96h, and the medium was 
replaced every 48h. Cultures were supplemented daily with several doses of (Pyr1)-
Apelin-13 (Bachem, Switzerland) ranging from 10
-11
 to 10
-5
 M. 
2.5 Morphometric Analysis 
Branching morphogenesis was monitored daily by photographing the explants 
using a stereomicroscope equipped with a camera (DP71, Olympus). At day 0 (D0: 0h) 
and day 4 (D4: 96h) of culture, the total number of peripheral airway buds in all lung 
explants was determined. Also, epithelial perimeter, epithelial area and total explant 
area were measured using Image J image processing and analysis software (version 
1.44, USA). For all experimental conditions, the results of the above mentioned 
morphometric parameters were expressed as D4/D0 ratio. 
2.6 Statistical analysis 
All quantitative data are presented as mean ± SEM. Statistical analysis was 
performed by one-way ANOVA and subsequently Student-Newman-Keuls test was 
used for post-test analysis, using SigmaStat 3.5 (Systat Software Inc., USA). Statistical 
significance was set at p < 0.05. 
  
3. RESULTS 
3.1 Apelin and APJ protein expression profile during rat lung development  
This study aimed to characterize apelin and APJ protein expression profile in the 
developing rat lung. Western blot and immunohistochemical studies were performed in 
order to characterize apelin and APJ protein expression levels as well as their 
localization and distribution during rat pulmonary development. Both proteins were 
assessed at five prenatal stages, specifically 13.5, 15.5, 17.5, 19.5 and 21.5 dpc and also 
in the adult. 
3.1.1 Apelin protein expression profile during rat lung development  
Western blot analysis revealed that apelin is expressed throughout all studied 
gestational ages in fetal lung as well as in the adult lung (Fig. 1). Apelin expression 
levels were maximal at the earliest gestational age studied, 13.5 dpc, early 
pseudoglandular stage in lung development, and then declined irregularly towards the 
end of gestation. Lowest apelin expression levels in prenatal period were detectable at 
17.5 dpc, late pseudoglandular stage. In the adult rat lung, apelin expression levels 
decline to a statistically significant remarkable minimum. 
Regarding immunohistochemical studies (Fig. 2), at the earliest gestational age 
studied, 13.5 dpc, apelin-positive cells are detected in both major tissues shaping the 
embryonic lung, epithelium and mesenchyme, in an extensive fashion (Fig. 2, A and 
A’). At 15.5 dpc, immunostaining was observed in the epithelium of the developing 
airways as well as in the mesenchyme surrounding the airways and also in the 
endothelium (Fig. 2, B and B’). At late pseudoglandular stage, 17.5 dpc, apelin 
immunostaining is observed in the whole organ, more intensely in the epithelial lining 
of the airways, also in surrounding mesenchyme and the vascular endothelium (Fig. 2, 
C and C’). The same expression pattern is detected in canalicular stage of development, 
19.5 dpc (Fig. 2, D and D’). At the later gestational age, 21.5 dpc, apelin 
immunostaining is primarily associated with both bronchial and alveolar epithelium and 
the vascular endothelium (Fig. 2, E and E’). The adult rat lung seems to exhibit a 
dissimilar expression profile from the one observed during gestational stages, bronchial 
epithelial staining and endothelial expressions are no longer predominant, alveolar 
epithelium has more significant expression, and there is also positive immunostaining 
detectable in blood (Fig. 2, F and F’). 
3.1.2 APJ protein expression profile during rat lung development 
Western blot analysis of the apelin receptor, APJ, revealed immunoreactivity for 
specific bands correlating to an expected molecular mass of ~42 kDa for the 
unglycosylated monomeric receptor as well as bands of higher molecular mass 
consistent with glycosylated monomeric receptor, ~45 kDa. Additional bands consistent 
in molecular weight to multiples of the monomer were also observed, dimeric receptor 
species at 90-95 kDa, and oligomeric receptor species at 125-135 kDa. 
Both monomeric and multimeric forms of the apelin receptor were expressed 
thoughout all studied gestational ages in fetal lung as well as in the adult, although 
exhibiting different expression profiles (Fig. 3). As for the monomeric protein (Fig. 
3A), highest expression levels were detected at the earliest gestational age studied, 13.5 
dpc, decreasing progressively at 15.5 and 17.5 dpc, the latter being the stage in which 
expression level was lowest during the prenatal period. Stages 19.5 and 21.5 dpc show a 
slight increase in the protein expression levels comparing to 17.5 dpc, nonetheless the 
same progressively decreasing tendency in APJ monomer protein expression during 
development prevails. Lowest expression levels with statistically significance were 
detected in the adult rat lung. Regarding the dimeric form of the receptor (Fig. 3B), 
despite no statistical difference established, adult rat lung has the highest expression 
level detected. APJ dimeric expression levels throughout all gestational ages studied 
remained mostly unvarying. Regarding the oligomeric form of the receptor (Fig. 3C), 
again highest expression levels were detected at the earliest gestational age studied, 13.5 
dpc, decreasing progressively into the later gestational age. Also for this form of the 
receptor, lowest expression levels were detected in the adult rat lung. 
Considering immunohistochemistry data, at the earliest gestational stages 
studied, 13.5 and 15.5 dpc, apelin receptor immunoreactivity observed has a very 
similar distribution pattern to that of apelin immunoreactivity (Fig. 4). In the first, there 
is APJ-positive cells in both epithelial and mesenchymal tissue with comparable 
intensity. At the latter stage, positivity is detected in the epithelium of the airways, in 
the mesenchyme surrounding the airways and also in the endothelium (Fig. 4, A-B and 
A’-B’). At stage 17.5 dpc, although there is widespread staining detectable in the organ, 
it is more intense in the cells of the epithelial lining of the airways and staining is 
predominantly nuclear, there is also weaker staining in the vascular endothelium and 
surrounding areas (Fig. 4, C and C’). At one of the later gestational ages studied, 19.5 
dpc, it is also observed a broad distribution of the apelin receptor in the fetal lung, but 
immunoreactivity is more intense in the airway epithelial cells, in which positivity is 
detected in the nucleus, the cytoplasm and the membrane (Fig. 4, D and D’). By the end 
of gestation at 21.5 dpc, APJ expression is also related mainly to the bronchial and 
alveolar epithelium, which is the predominant tissue at this stage, weaker expression is 
detectable in the endothelial lining of the vasculature (Fig. 4, E and E’). In the adult rat 
lung, a weak APJ expression is detectable in the alveoli that comprises most of the 
respiratory tissue, and also in the endothelial lining of the vessels and the smooth 
muscle surrounding bronchi and large pulmonary vessels. More intense staining is 
detected in the nucleus and cytoplasm of the epithelial cells of the respiratory bronchi 
(Fig. 4, F and F’). 
3.2 Effects of Apelin supplementation in fetal lung explant cultures 
This study also aimed to elucidate the role of apelin in the developing rat lung. 
Therefore, apelin supplementation studies were carried out in the fetal lung explant 
culture model. Normal fetal lung explants were treated with different doses of 
recombinant (Pyr1)-Apelin-13. In Figure 5, representative examples of normal fetal 
lung explants treated with increasing Apelin-13 doses are illustrated. Apelin-13 appears 
to have an inhibitory effect on lung explants growth, except with the lowest dose tested 
as shown by the morphometric analysis data summarized in Figure 6. In fetal lung 
explants, regardless of a slight increase in growth verified in all the morphometric 
parameters induced by the lowest dose of Apelin-13 tested, no statistical significance 
against the absence of apelin treatment was observed. In contrast, supplementation with 
the highest dose, 10
-5
M, significantly reduced whole explant growth when compared 
with the lowest dose of Apelin-13 tested, demonstrated by both epithelial and external 
explant area. Also, considering the epithelial perimeter, a significant inhibitory effect is 
induced by the highest dose tested when compared to lack of supplementation or 
treatment with low Apelin-13 doses, 10
-11
 and 10
-9
M. Considering the number of 
peripheral airway buds, no significant statistical difference was observed. 
3.3 Apelin supplementation effects on MAPK signaling pathway 
In order to further investigate the underlying molecular mechanisms responsible 
for the effect of Apelin on fetal lung growth, the dose effect of apelin on mitogen-
activated protein kinases signaling was determined. Expression levels of p38, JNK1/2, 
and ERK1/2 were assessed by Western blot in pooled samples (N=12) of Apelin-13 
treated fetal lung explants. Activation of MAPKs is regulated by phosphorylation, thus 
both unphosphorylated and phosphorylated protein states were assessed, as shown in 
Figure 7. For each protein the ratio of phosphorylated to unphosphorylated form was 
determined (Fig.8) revealing that apelin treatment induced a dose dependent decrease in 
activation of both p38 and JNK, since increasing doses of apelin gradually reduced 
phosphorylation of these two MAP kinases (Fig. 8, A and B). In contrast, the highest 
dose of Apelin tested induced activation of ERK1/2, whereas supplementation with 
lower doses of apelin reduced phosphorylation when compared with absence of apelin 
treatment (Fig. 8C). 
  
3. DISCUSSION 
This study analyses for the first time, fetal pulmonary protein expression profile 
of both components of the apelinergic system, apelin and APJ, by Western blot and 
Imunohistochemistry, parallel comparison with the adult profile is also presented. 
Additionally, in vitro apelin supplementation studies were performed in fetal lung 
explants in order to elucidate its putative role in branching morphogenesis and we 
further investigated MAPK signaling contribution to the effects of apelin on fetal lung 
growth. We demonstrated that both components of the apelinergic system are 
constitutively expressed in the lung during all studied gestational ages and also in the 
adult. Western blot analysis yield important data regarding the characterization of apelin 
and APJ in lung development. Apelin immunoreactivity has been previously detected as 
a band of approximately 16 kDa in different tissue lysates [28], as it is observed in our 
sample lysates. In fetal lung, apelin protein expression levels have a maximum at an 
early stage in development (13.5 dpc), in all the other gestational ages studied 
expression levels are lower, and its minimum is reached  in the adult tissue. This fact, 
points towards, possibly, a more relevant role of this peptide during early stages of lung 
development. Regarding apelin receptor, western blot analysis made it possible to 
observe that this receptor exits in a variety of presentations in the pulmonary tissue, 
which include post-translational modifications and multimeric arrangements. At lower 
molecular weight, both unglycolysated and glycolysated forms (42 and 45 kDa) of the 
monomeric receptor species are present in all studied gestational ages. At higher 
molecular weights, corresponding to multiples of the monomer, dimeric (~90-95 kDa) 
and oligomeric (~125-135 kDa) receptor species were observed. According to the 
literature many GPCRs, besides the monomeric form, are expressed as dimers and 
oligomers, but it is also common for GPCR to appear as homo- and hetero-dimers and 
oligomers [5,41,33]. Whether APJ multimeric species observed in the fetal and adult 
pulmonary tissues in our study correspond to homo- or hetero- multiples of the receptor 
is still not known and could only be clarified by further studies. Nonetheless, it was 
already demonstrated in vitro that APJ can form heterodimers with angiotensin II AT1 
receptor [7]. Moreover immunohistochemical studies performed in our lab revealed that 
all renin-angiotensin system components, including AT1 and AT2 receptors, are 
expressed in fetal lung throughout the gestational ages also characterized in this study 
[36].  
The immunohistochemical studies were performed to further characterize the 
presence of apelin and APJ in the pulmonary tissue. These studies allow us to conclude 
that apelin lung expression is mainly related to both airways and vasculature during the 
developmental stages studied. Apelin immunostaining was detected in the airways 
lining, either in bronchial epithelium throughout gestation, as well as in the alveolar 
epithelium as it gradually appeared. Regarding the vasculature, positive immunostaining 
was detected in the endothelial lining of the blood vessels from15.5 dpc to 21.5 dpc. 
Whereas in the adult rat lung, apelin presence is strongest in the alveolar epithelium, 
less intense in the bronchial epithelium and nearly absent in the vasculature. 
Interestingly there is apelin immunoreactivity in the content of the pulmonary blood 
vessels which is not associated with blood cells, which may possibly be in accordance 
with previous reports that detected plasma levels of apelin in humans and consequently 
showed that apelin is a circulating peptide [6,13,16]. Few studies report apelin 
localization in pulmonary tissue by immunohistochemistry, showing intense staining in 
the respiratory epithelium and smooth muscle in normal adult human tissues [10], and 
also presence in bronchial and alveolar epithelial cells in neonatal rat lung [47]. 
Immunohistochemistry for the receptor protein revealed that APJ localization is 
predominantly associated with the pulmonary airways in the developmental stages 
studied. Most striking is the distribution of the receptor within the bronchial epithelium, 
where APJ can be detected either in the cytoplasm, the membrane and also the nucleus 
of these epithelial cells, nuclear localization of the receptor appears as early as 15.5dpc 
and is detectable in all subsequent stages. Apelin receptor nuclear localization is 
therefore indicative of nuclear translocation of APJ occurring probably only in certain 
cell populations within pulmonary tissue. To date, there have been many reports of the 
intercellular localization and trafficking of GPCRs, although GPCRs are best known as 
cell surface mediators of signal transduction there is an increasing number of reports of 
GPCRs capable of nuclear translocation [15]. Thus far, besides our findings in 
pulmonary tissue there is only one report showing that apelin receptor exhibits nuclear 
localization occurring in brain tissue [27]. This nuclear localization of apelin receptor 
points out to previously unforeseen functions of this receptor as a modulator of nuclear 
transcription that are worth investigating, in addition to the well-established role of this 
receptor family at the cell surface. In the adult rat lung, APJ immunostaining is most 
intense in the bronchial epithelium and respiratory epithelium where it is observed that 
expression is cytoplasmatic, membranous and nuclear. Additionally, lower intensity 
immunostaining was detected in the alveolar epithelium, the endothelium and also the 
smooth muscle around the bronchi. These results match previous findings of 
immunoreactivity in human lung tissue that showed that APJ is expressed in endothelial 
cells and smooth muscle of small pulmonary vessels, and also demonstrated receptor 
immunoreactivity in bronchial epithelial cells as well as in the endothelium and in 
smooth muscle cells in rat tissue [23]. The fetal lung displays the necessary machinery 
for Apelin/APJ signaling, and the epithelium might act as both the physiological source 
of apelin and also as a target tissue for apelin to exert its physiological action during 
fetal lung development. 
Our findings on the presence and significant features regarding the 
characterization of both components of this peptidergic system on the pulmonary tissue 
during development led us to hypothesize that it might have an underlying role in lung 
branching morphogenesis. Hence, in order to begin exploring this assumption, in vitro 
apelin supplementation studies were performed in the fetal lung explant culture model. 
The morphometric analysis on the fetal lung explants exposed to increasing doses of 
apelin in culture, showed a steady tendency for an inhibition of lung explant growth, 
especially significant in the highest dose tested. It is well known that negative molecular 
mediators are essential in pulmonary development given that there is a strict dependence 
on the balance between inductive and suppressive mechanisms occurring in this 
process. Therefore, orderly branching morphogenesis also depends on multiple 
antagonists [34,48]. Interestingly, it was recently demonstrated in the same in vitro 
culture model, that angiotensin II (Ang II) supplementation induced an increase in lung 
explants growth [36]. Most striking about these findings is its straight association with 
an emerging key feature of the Apelin/APJ system, its interaction with the renin-
angiotensin system. Currently the relation between these two systems is described to be 
a direct interaction of the two systems at both molecular and transcriptional levels to 
mediate opposing physiological actions [2]. APJ and AT1 receptor-receptor interactions 
are presently accounted as the potential molecular mechanism of crosstalk responsible 
for this reciprocal counter-regulation between apelin and Ang II pathways, since it was 
observed in vitro that the respective receptors can form heterodimers and that this 
heterodimerisation influences downstream signaling [7]. Our observations on fetal lung 
growth are in accordance with others reporting that the proposed effects of the apelin-
APJ system are opposite to those of the Ang II- AT1 receptor pathway [7,44].  
On one hand, coupling of apelin to its receptor APJ has been reported to activate MAP 
kinases signaling pathways [1,28]. On the other hand, MAPK were shown to be 
important signaling pathway for murine lung development through regulation of 
branching morphogenesis, epithelial cell proliferation, cell survival and differentiation 
[24]. Hence, evaluating MAPK signaling in the context of elucidating apelin’s effects 
on fetal lung growth was regarded pertinent. Our results clearly show dose dependent 
decrease in activation of both p38 and JNK induced by apelin treatment as well as 
activation of ERK1/2 induced by the highest dose of apelin tested. In previous studies 
enhanced fetal lung branching was associated with stimulation of p38 phosphorylation 
[37] likewise, lung growth inhibition induced by AT1 antagonist was reported to be 
mediated by a decrease of p38 and JNK phosphorylation [36]. Therefore, apelin 
supplementation inhibitory effect on lung growth is most likely mediated by decreased 
p38 and JNK phosphorylation. It is common for MAP kinases to share substrates and to 
integrate signals from individual cascades not only during the early signal transduction 
events and within the kinase cascades, but also at the level of substrate phosphorylation 
[8]. In view of this, it is only reasonable to assume that these apparent discrepancies in 
the expression of p38, JNK and ERK1/2 might reflect cross-cascade interactions taking 
place in order to restore intracellular signaling balance. 
In conclusion, the data here presented provides the first evidence of the presence 
of an apelinergic system operating in the developing lung. Our results also demonstrated 
that the apelin receptor exhibits nuclear localization in lung epithelial cells, which 
unveils an important and novel feature of this system that suggest unanticipated 
functions for this G-protein coupled receptor in nuclear transcription regulation. 
Moreover, it is also demonstrated that apelin’s inhibitory effect on fetal lung growth is 
associated with inhibition of p38 and JNK signaling pathways. We have further 
characterized this novel peptidergic system in the developing lung. 
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5. FIGURE AND LEGENDS 
 
Figure 1. Protein levels of apelin during fetal rat lung development. Western blot 
analysis of apelin performed in several gestational ages, from 13.5 until 21.5 dpc and 
also in the adult. Representative blot examples is shown. All protein levels were 
normalized to β-tubulin, which was used as loading control. Densitometric analyses of 
three blots (N=3) are plotted above the representative blots. Values represent mean ± 
SE. p < 0,05: * vs. adult; # vs. 17.5 dpc; § vs. 15.5 dpc. 
 
Figure 2. Apelin expression pattern during fetal rat lung development. Apelin is present 
throughout all stages of lung development from early 13.5 dpc until late 21.5 dpc and 
also in the adult. Representative immunohistochemistry staining of (A-E) developing 
lung (F) adult lung. (A) original magnification ×200 (A’) original magnification ×400. 
aw = developing airway, bv = blood vessel. 
 
 
Figure 3. Protein levels of APJ during fetal rat lung development. Western blot analysis 
of APJ protein levels in developing rat lung at various fetal ages and also in the adult. 
(A) monomeric (B) dimeric and (C) oligomeric forms of the receptor were detected. 
Representative blots examples are shown. All protein levels were normalized to β-
tubulin, which was used as loading control. Densitometric analyses of three blots (N=3) 
are plotted above the representative blots. Values represent mean ± SE. p < 0,05: * vs. 
adult; # vs. 17.5 dpc,  vs. 19.5 dpc, vs. 21.5 dpc, § vs. 15.5 dpc. 
 
Figure 4. APJ expression pattern during fetal rat lung development. APJ is present 
throughout all stages of lung development from early 13.5 dpc until late 21.5 dpc and 
also in the adult. Representative immunohistochemistry staining of (A-E) developing 
lung (F) adult lung. (A) original magnification ×200 (A’) original magnification ×400. 
aw = developing airway, bv = blood vessel. 
 
 
Figure 5. Branching morphogenesis in rat lung explant culture system Representative 
examples of control and fetal lung explants treated with increasing Apelin-13 
concentrations. Upper panel shows representative photograph of lung explant at 13.5 
dpc at culture day 0 (D0). Bottom panel shows representative photograph of lung 
explant at 13.5 dpc, treated with several Apelin-13 concentrations, at day 4 in culture 
(D4). Original magnification ×40.  
 Figure 6. Morphometric analysis of fetal rat lung explants supplemented with 
increasing apelin concentrations. Several parameters in control and treated explants 
were analyzed, (A) epithelial perimeter, (B) epithelial area, (C) number of total airway 
buds and (D) total explant area. Measures of ten lung explants (N=10) per condition are 
plotted above. Results are expressed as D4/D0 ratio. Values represent mean ± SE. p < 
0,05: * vs. 10
-11
 M, # vs. 0 M (control), § vs. 10
-9
 M. 
 Figure 7. MAP kinases activity in fetal rat lung explants treated with increasing apelin 
concentrations. Western blot analysis of p38, JNK1/2, and ERK1/2 in pooled samples 
(N=12) of Apelin-13 treated fetal lung explants. Both unphosphorylated and 
diphosphorylated forms of p38 (dp-p38), p44/42 (dp-p44/42), JNK1/2 (dp-JNK1/2) 
were assessed. β-tubulin was used as loading control. 
 
 
Figure 8. Effects of apelin on MAPK signaling in fetal rat lung explants. Ratio of 
phosphorylated to unphosphorylated form was determined for (A) p38, (B) JNK1/2 and 
(C) ERK1/2. All protein levels were normalized to β-tubulin, which was used as loading 
control. Densitometric analysis results are presented as arbitrary units. 
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